skip to main content

Recent Updates of Stem Cell Therapy in Spontaneous Intracerebral Haemorrhage Patients: A Review Article

I Wayan Niryana  -  Neurosurgery Sub-Department, Faculty of Medicine Universitas Udayana, Indonesia, Indonesia
Ida Bagus Adiguna Wibawa  -  , Indonesia
*Gede Febby Pratama Kusuma  -  Neurosurgery Sub-Department, Faculty of Medicine Universitas Udayana, Bali - Indonesia, Indonesia

Citation Format:
Abstract

Background: Spontaneous intracerebral haemorrhage (sICH) is a severe neurological condition with high disability and mortality rates globally. Effective therapeutic strategies to overcome the acute and long-term problems caused by sICH are still lacking. Mesenchymal stem cell (MSCs) therapy with the neuroprotective and neuroregenerative properties has the potential to overcome the complex brain injury mechanisms caused by sICH.

Objective: This review highlights the recent pre-clinical and clinical findings about MSCs therapy in sICH case and their mechanisms in promoting neurological recovery.

Methods: This is a literature review study. Study reports available from various accredited database such as PubMed and Google Scholar are collected using the following keywords: ((“stroke” or “intracerebral haemorrhage”)) and (“stem cell”).

Results: Pre-clinical studies proved that MSCs therapy can resolved the secondary brain insult caused by sICH and improved the brain functional and clinical status. The clinical studies proved that MSCs therapy are safe and well tolerated in human bodies. There were also beneficial MSCs therapy effects in sICH patients. However, the clinical studies results were still lacking and some were inconclusive.

Conclusion: The preclinical studies of stem cell therapy in spontaneous intracerebral haemorrhage showed promising evidences and the potential of stem cell therapy for clinical use. However, the clinical studies were still lacking. Further clinical studies are needed to confirm the neuroprotective and neuroregenerative benefits of MSCs therapy from the pre-clinical studies.
Fulltext View|Download
Keywords: neuroprotective; neuroregenerative; spontaneous intracerebral haemorrhage; stem cell therapy

Article Metrics:

  1. Turnbull MT, Zubair AC, Meschia JF, et al. Mesenchymal stem cells for hemorrhagic stroke: Status of preclinical and clinical research. NPJ Regen Med. 2019; 4: 10. DOI: 10.1038/s41536-019-0073-8
  2. Hovhannisyan L, Khachatryan S, Khamperyan A, et al. A review and meta-analysis of stem cell therapies in stroke patients: Effectiveness and safety evaluation. Neurol Sci. 2024; 45: 65-74. DOI: 10.1007/s10072-023-07032-z
  3. Nagpal A, Choy FC, Howell S, et al. Safety and effectiveness of stem cell therapies in early-phase clinical trials in stroke: A systematic review and meta-analysis. Stem Cell Res Ther. 2017; 8: 191. DOI: 10.1186/s13287-017-0643-x
  4. Li C, Qin H, Zeng L, et al. Efficacy of stem cell therapy in animal models of intracerebral hemorrhage: An updated meta-analysis. Stem Cell Res Ther. 2022; 13: 452. DOI: 10.1186/s13287-022-03158-7
  5. Singh M, Pandey PK, Bhasin A, et al. Application of stem cells in stroke: A multifactorial approach. Front Neurosci. 2020; 14: 473. DOI: 10.3389/fnins.2020.00473
  6. Kim JT, Youn DH, Kim BJ, et al. Recent stem cell research on hemorrhagic stroke : An update. J Korean Neurosurg Soc. 2022; 65: 161-72. DOI: 10.3340/jkns.2021.0126
  7. Chen Y, Wright N, Guo Y, et al. Mortality and recurrent vascular events after first incident stroke: A 9-year community-based study of 0.5 million chinese adults. Lancet Glob Health. 2020; 8: e580-e90. DOI: 10.1016/S2214-109X(20)30069-3
  8. Gong YH, Hao SL, and Wang BC. Mesenchymal stem cells transplantation in intracerebral hemorrhage: Application and challenges. Front Cell Neurosci. 2021; 15: 653367. DOI: 10.3389/fncel.2021.653367
  9. Ahn SY, Chang YS, Sung DK, et al. Mesenchymal stem cells prevent hydrocephalus after severe intraventricular hemorrhage. Stroke. 2013; 44: 497-504. DOI: 10.1161/STROKEAHA.112.679092
  10. Bhasin A, Srivastava MV, Kumaran SS, et al. Autologous mesenchymal stem cells in chronic stroke. Cerebrovasc Dis Extra. 2011; 1: 93-104. DOI: 10.1159/000333381
  11. Chang Z, Mao G, Sun L, et al. Cell therapy for cerebral hemorrhage: Five year follow-up report. Exp Ther Med. 2016; 12: 3535-40. DOI: 10.3892/etm.2016.3811
  12. Li ZM, Zhang ZT, Guo CJ, et al. Autologous bone marrow mononuclear cell implantation for intracerebral hemorrhage-a prospective clinical observation. Clin Neurol Neurosurg. 2013; 115: 72-6. DOI: 10.1016/j.clineuro.2012.04.030
  13. Tsang KS, Ng CPS, Zhu XL, et al. Phase i/ii randomized controlled trial of autologous bone marrow-derived mesenchymal stem cell therapy for chronic stroke. World J Stem Cells. 2017; 9: 133-43. DOI: 10.4252/wjsc.v9.i8.133
  14. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (safecell): A systematic review and meta-analysis of clinical trials. PLoS One. 2012; 7: e47559. DOI: 10.1371/journal.pone.0047559
  15. Durand NC, Kim HG, Patel VN, et al. Mesenchymal stem cell therapy in acute intracerebral hemorrhage: A dose-escalation safety and tolerability trial. Neurocrit Care. 2023. DOI: 10.1007/s12028-023-01897-w

Last update:

No citation recorded.

Last update:

No citation recorded.